



872 W. Baltimore Pike, West Grove, PA 19380  
 800-367-5296, 610-869-4024, FAX:  
 610-869-0171  
 cuserv@jacksonimmuno.com  
 www.jacksonimmuno.com  
 www.jireurope.com

Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II

## SAFETY DATA SHEET

### Cy3-Conjugated Antibody, Streptavidin, and Purified Serum Protein, freeze-dried with preservative

**SECTION 1: Identification of the substance/mixture and of the company/undertaking**

**1.1 Product identifier**

**Product name:** Cy3-Conjugated Antibodies, Streptavidin, and Purified Serum Proteins, freeze-dried with preservative

**Product code:**

001-160-003	107-165-142	111-166-003	115-165-146	212-165-106	309-166-003	515-165-062
003-160-003	107-166-142	111-166-045	115-165-164	212-165-168	309-166-008	515-165-071
005-160-003	108-165-003	111-166-046	115-165-166	212-166-168	309-166-043	515-165-072
005-160-006	108-165-008	111-166-047	115-165-174	213-162-177	312-165-003	703-165-155
007-160-003	108-166-003	111-167-003	115-165-205	301-165-003	312-165-020	703-166-155
009-160-003	109-165-003	112-165-003	115-165-206	303-165-003	312-165-044	705-165-003
009-160-006	109-165-006	112-165-006	115-165-207	303-165-006	312-165-045	705-165-147
009-160-007	109-165-008	112-165-008	115-165-208	303-165-008	312-165-046	705-166-147
009-160-008	109-165-011	112-165-020	115-165-209	303-166-003	312-165-047	706-165-148
009-160-011	109-165-043	112-165-044	115-166-003	304-165-003	312-165-048	706-166-148
009-160-012	109-165-044	112-165-062	115-166-006	304-165-008	312-165-049	709-165-073
009-160-050	109-165-064	112-165-068	115-166-008	305-165-003	312-166-045	709-165-098
009-160-051	109-165-088	112-165-071	115-166-020	305-165-006	313-165-003	709-165-149
011-160-003	109-165-097	112-165-072	115-166-062	305-165-008	313-165-045	709-166-073
012-160-003	109-165-098	112-165-075	115-166-068	305-165-045	313-165-046	709-166-098
012-160-050	109-165-127	112-165-143	115-166-071	305-165-046	313-165-047	709-166-149
013-160-003	109-165-129	112-165-167	115-166-072	305-165-047	313-166-003	711-165-152
015-160-003	109-166-003	112-165-175	115-166-075	305-166-003	313-167-003	711-166-152
015-160-006	109-166-006	112-166-003	115-167-003	305-166-006	315-165-003	711-167-003
015-160-007	109-166-008	112-166-062	115-167-020	305-166-008	315-165-006	712-165-150
015-160-008	109-166-011	112-166-068	123-165-021	305-166-045	315-165-008	712-165-153
015-160-050	109-166-064	112-166-071	127-165-099	305-166-046	315-165-020	712-166-150
016-160-084	109-166-088	112-166-072	127-165-160	305-166-047	315-165-044	712-166-153
017-160-003	109-166-097	112-166-075	200-162-037	305-167-003	315-165-045	712-167-003
017-160-006	109-166-098	112-167-003	200-162-156	307-165-003	315-165-046	713-165-003
101-165-003	109-166-127	114-165-003	200-162-211	307-166-003	315-165-047	713-165-147
101-165-165	109-166-129	115-165-003	205-162-176	308-165-003	315-165-048	713-166-147
101-166-003	109-167-003	115-165-006	205-165-108	309-165-003	315-165-049	715-165-020
102-165-003	109-167-043	115-165-008	209-165-082	309-165-006	315-166-003	715-165-140
102-165-006	111-165-003	115-165-020	209-165-088	309-165-008	315-166-045	715-165-150
102-165-008	111-165-006	115-165-044	209-165-097	309-165-011	315-166-046	715-165-151
103-165-155	111-165-008	115-165-062	209-165-098	309-165-015	315-166-047	715-166-020
106-165-003	111-165-045	115-165-068	211-162-171	309-165-064	315-167-003	715-166-150
106-165-006	111-165-046	115-165-071	211-165-109	309-165-082	323-165-021	715-166-151
106-165-008	111-165-047	115-165-072	212-165-082	309-165-095	415-165-166	715-167-003
106-166-003	111-165-144	115-165-075	212-165-104	309-165-107	515-165-003	805-165-180

**SDS #:** 17EU

**Product description:**

001-160-003	Cy3-ChromPure Bovine IgG, whole molecule
003-160-003	Cy3-ChromPure Chicken IgY (IgG), whole molecule
005-160-003	Cy3-ChromPure Goat IgG, whole molecule
005-160-006	Cy3-ChromPure Goat IgG, F(ab') <sub>2</sub> fragment
007-160-003	Cy3-ChromPure Syrian Hamster IgG, whole molecule
009-160-003	Cy3-ChromPure Human IgG, whole molecule
009-160-006	Cy3-ChromPure Human IgG, F(ab') <sub>2</sub> fragment
009-160-007	Cy3-ChromPure Human IgG, Fab fragment
009-160-008	Cy3-ChromPure Human IgG, Fc fragment
009-160-011	Cy3-ChromPure Human IgA, serum
009-160-012	Cy3-ChromPure Human IgM (myeloma), whole molecule
009-160-050	Cy3-ChromPure Human Transferrin
009-160-051	Cy3-ChromPure Human Albumin
011-160-003	Cy3-ChromPure Rabbit IgG, whole molecule
012-160-003	Cy3-ChromPure Rat IgG, whole molecule
012-160-050	Cy3-ChromPure Rat Transferrin
013-160-003	Cy3-ChromPure Sheep IgG, whole molecule
015-160-003	Cy3-ChromPure Mouse IgG, whole molecule
015-160-006	Cy3-ChromPure Mouse IgG, F(ab') <sub>2</sub> fragment
015-160-007	Cy3-ChromPure Mouse IgG, Fab fragment
015-160-008	Cy3-ChromPure Mouse IgG, Fc fragment
015-160-050	Cy3-ChromPure Mouse Transferrin
016-160-084	Cy3-Streptavidin
017-160-003	Cy3-ChromPure Donkey IgG, whole molecule
017-160-006	Cy3-ChromPure Donkey IgG, F(ab') <sub>2</sub> fragment
101-165-003	Cy3-AffiniPure Goat Anti-Bovine IgG (H+L)
101-165-165	Cy3-AffiniPure Goat Anti-Bovine IgG (H+L) (min X Ar Hms, Hu, Ms, Rat Sr Prot)
101-166-003	Cy3-AffiniPure F(ab') <sub>2</sub> Fragment Goat Anti-Bovine IgG (H+L)
102-165-003	Cy3-AffiniPure Goat Anti-Cat IgG (H+L)
102-165-006	Cy3-AffiniPure Goat Anti-Cat IgG, F(ab') <sub>2</sub> Fragment Specific
102-165-008	Cy3-AffiniPure Goat Anti-Cat IgG, Fc Fragment Specific
103-165-155	Cy3-AffiniPure Goat Anti-Chicken IgY (IgG) (H+L) (min X Bov, Gt, GP, Sy Hms, Hrs, Hu, Ms, Rb, Rat, Shp Sr Prot)

106-165-003 Cy3-AffiniPure Goat Anti-Guinea Pig IgG (H+L)  
106-165-006 Cy3-AffiniPure Goat Anti-Guinea Pig IgG, F(ab')<sub>2</sub> Fragment Specific  
106-165-008 Cy3-AffiniPure Goat Anti-Guinea Pig IgG, Fc Fragment Specific  
106-166-003 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Goat Anti-Guinea Pig IgG (H+L)  
107-165-142 Cy3-AffiniPure Goat Anti-Syrian Hamster IgG (H+L) (min X Bov,Hrs,Hu,Ms,Rb,Rat Sr Prot)  
107-166-142 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Goat Anti-Syrian Hamster IgG (H+L) (min X Bov,Hrs,Hu,Ms,Rb,Rat Sr Prot)  
108-165-003 Cy3-AffiniPure Goat Anti-Horse IgG (H+L)  
108-165-008 Cy3-AffiniPure Goat Anti-Horse IgG, Fc Fragment Specific  
108-166-003 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Goat Anti-Horse IgG (H+L)  
109-165-003 Cy3-AffiniPure Goat Anti-Human IgG (H+L)  
109-165-006 Cy3-AffiniPure Goat Anti-Human IgG, F(ab')<sub>2</sub> Fragment Specific  
109-165-008 Cy3-AffiniPure Goat Anti-Human IgG, Fc<sub>γ</sub> Fragment Specific  
109-165-011 Cy3-AffiniPure Goat Anti-Human Serum IgA, α Chain Specific  
109-165-043 Cy3-AffiniPure Goat Anti-Human IgM, Fc<sub>5μ</sub> Fragment Specific  
109-165-044 Cy3-AffiniPure Goat Anti-Human IgG + IgM (H+L)  
109-165-064 Cy3-AffiniPure Goat Anti-Human IgA + IgG + IgM (H+L)  
109-165-088 Cy3-AffiniPure Goat Anti-Human IgG (H+L) (min X Bov,Hrs,Ms Sr Prot)  
109-165-097 Cy3-AffiniPure Goat Anti-Human IgG, F(ab')<sub>2</sub> Fragment Specific (min X Bov,Hrs,Ms Sr Prot)  
109-165-098 Cy3-AffiniPure Goat Anti-Human IgG, Fc<sub>γ</sub> Fragment Specific (min X Bov,Hrs,Ms Sr Prot)  
109-165-127 Cy3-AffiniPure Goat Anti-Human IgG + IgM (H+L) (min X Bov Sr Prot)  
109-165-129 Cy3-AffiniPure Goat Anti-Human IgM, Fc<sub>5μ</sub> Fragment Specific (min X Bov Sr Prot)  
109-166-003 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Goat Anti-Human IgG (H+L)  
109-166-006 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Goat Anti-Human IgG, F(ab')<sub>2</sub> Fragment Specific  
109-166-008 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Goat Anti-Human IgG, Fc<sub>γ</sub> Fragment Specific  
109-166-011 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Goat Anti-Human Serum IgA, α Chain Specific  
109-166-064 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Goat Anti-Human IgA + IgG + IgM (H+L)  
109-166-088 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Goat Anti-Human IgG (H+L) (min X Bov,Hrs,Ms Sr Prot)  
109-166-097 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Goat Anti-Human IgG, F(ab')<sub>2</sub> Fragment Specific (min X Bov,Hrs,Ms Sr Prot)  
109-166-098 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Goat Anti-Human IgG, Fc<sub>γ</sub> Fragment Specific (min X Bov,Hrs,Ms Sr Prot)  
109-166-127 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Goat Anti-Human IgG + IgM (H+L) (min X Bov Sr Prot)  
109-166-129 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Goat Anti-Human IgM, Fc<sub>5μ</sub> Fragment Specific (min X Bov Sr Prot)  
109-167-003 Cy3-AffiniPure Fab Fragment Goat Anti-Human IgG (H+L)  
109-167-043 Cy3 - AffiniPure Fab Fragment Goat Anti-Human IgM, Fc<sub>5μ</sub> Fragment Specific  
111-165-003 Cy3-AffiniPure Goat Anti-Rabbit IgG (H+L)  
111-165-006 Cy3-AffiniPure Goat Anti-Rabbit IgG, F(ab')<sub>2</sub> Fragment Specific  
111-165-008 Cy3-AffiniPure Goat Anti-Rabbit IgG, Fc Fragment Specific  
111-165-045 Cy3-AffiniPure Goat Anti-Rabbit IgG (H+L) (min X Hu Sr Prot)  
111-165-046 Cy3-AffiniPure Goat Anti-Rabbit IgG, Fc Fragment Specific (min X Hu Sr Prot)  
111-165-047 Cy3-AffiniPure Goat Anti-Rabbit IgG, F(ab')<sub>2</sub> Fragment Specific (min X Hu Sr Prot)  
111-165-144 Cy3-AffiniPure Goat Anti-Rabbit IgG (H+L) (min X Hu,Ms,Rat Sr Prot)  
111-166-003 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Goat Anti-Rabbit IgG (H+L)  
111-166-045 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Goat Anti-Rabbit IgG (H+L) (min X Hu Sr Prot)  
111-166-046 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Goat Anti-Rabbit IgG, Fc Fragment Specific (min X Hu Sr Prot)  
111-166-047 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Goat Anti-Rabbit IgG, F(ab')<sub>2</sub> Fragment Specific (min X Hu Sr Prot)  
111-167-003 Cy3-AffiniPure Fab Fragment Goat Anti-Rabbit IgG (H+L)  
112-165-003 Cy3-AffiniPure Goat Anti-Rat IgG (H+L)  
112-165-006 Cy3-AffiniPure Goat Anti-Rat IgG, F(ab')<sub>2</sub> Fragment Specific  
112-165-008 Cy3-AffiniPure Goat Anti-Rat IgG, Fc<sub>γ</sub> Fragment Specific  
112-165-020 Cy3-AffiniPure Goat Anti-Rat IgM, μ Chain Specific  
112-165-044 Cy3-AffiniPure Goat Anti-Rat IgG + IgM (H+L)  
112-165-062 Cy3-AffiniPure Goat Anti-Rat IgG (H+L) (min X Hu,Bov,Hrs Sr Prot)  
112-165-068 Cy3-AffiniPure Goat Anti-Rat IgG + IgM (H+L) (min X Hu,Bov,Hrs Sr Prot)  
112-165-071 Cy3-AffiniPure Goat Anti-Rat IgG, Fc<sub>γ</sub> Fragment Specific (min X Hu,Bov,Hrs Sr Prot)  
112-165-072 Cy3-AffiniPure Goat Anti-Rat IgG, F(ab')<sub>2</sub> Fragment Specific (min X Hu,Bov,Hrs Sr Prot)  
112-165-075 Cy3-AffiniPure Goat Anti-Rat IgM, μ Chain Specific (min X Hu,Bov,Hrs Sr Prot)  
112-165-143 Cy3-AffiniPure Goat Anti-Rat IgG (H+L) (min X Hu,Bov,Hrs,Rb Sr Prot)  
112-165-167 Cy3-AffiniPure Goat Anti-Rat IgG (H+L) (min X Ms,Hu,Bov,Hrs,Rb Sr Prot)  
112-165-175 Cy3-AffiniPure Goat Anti-Rat IgG, Light Chain\* Specific (min X Bov,Gt,Hrs,Hu,Ms,Rb,Shp Ig)  
112-166-003 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Goat Anti-Rat IgG (H+L)  
112-166-062 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Goat Anti-Rat IgG (H+L) (min X Hu,Bov,Hrs Sr Prot)  
112-166-068 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Goat Anti-Rat IgG + IgM (H+L) (min X Hu,Bov,Hrs Sr Prot)  
112-166-071 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Goat Anti-Rat IgG, Fc<sub>γ</sub> Fragment Specific (min X Hu,Bov,Hrs Sr Prot)  
112-166-072 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Goat Anti-Rat IgG, F(ab')<sub>2</sub> Fragment Specific (min X Hu,Bov,Hrs Sr Prot)  
112-166-075 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Goat Anti-Rat IgM, μ Chain Specific (min X Hu,Bov,Hrs Sr Prot)  
112-167-003 Cy3-AffiniPure Fab Fragment Goat Anti-Rat IgG (H+L)  
114-165-003 Cy3-AffiniPure Goat Anti-Swine IgG (H+L)  
115-165-003 Cy3-AffiniPure Goat Anti-Mouse IgG (H+L)  
115-165-006 Cy3-AffiniPure Goat Anti-Mouse IgG, F(ab')<sub>2</sub> Fragment Specific  
115-165-008 Cy3-AffiniPure Goat Anti-Mouse IgG, Fc<sub>γ</sub> Fragment Specific  
115-165-020 Cy3-AffiniPure Goat Anti-Mouse IgM, μ Chain Specific  
115-165-044 Cy3-AffiniPure Goat Anti-Mouse IgG + IgM (H+L)  
115-165-062 Cy3-AffiniPure Goat Anti-Mouse IgG (H+L) (min X Hu,Bov,Hrs Sr Prot)  
115-165-068 Cy3-AffiniPure Goat Anti-Mouse IgG + IgM (H+L) (min X Hu,Bov,Hrs Sr Prot)  
115-165-071 Cy3-AffiniPure Goat Anti-Mouse IgG, Fc<sub>γ</sub> Fragment Specific (min X Hu,Bov,Hrs Sr Prot)  
115-165-072 Cy3-AffiniPure Goat Anti-Mouse IgG, F(ab')<sub>2</sub> Fragment Specific (min X Hu,Bov,Hrs Sr Prot)  
115-165-075 Cy3-AffiniPure Goat Anti-Mouse IgM, μ Chain Specific (min X Hu,Bov,Hrs Sr Prot)  
115-165-146 Cy3-AffiniPure Goat Anti-Mouse IgG (H+L) (min X Hu,Bov,Hrs,Rb,Sw Sr Prot)  
115-165-164 Cy3-AffiniPure Goat Anti-Mouse IgG (subclasses 1+2a+2b+3), Fc<sub>γ</sub> Fragment Specific (min X Hu,Bov,Rb Sr Prot)  
115-165-166 Cy3-AffiniPure Goat Anti-Mouse IgG (H+L) (min X Rat,Hu,Bov,Hrs,Rb Sr Prot)  
115-165-174 Cy3-AffiniPure Goat Anti-Mouse IgG, Light Chain\* Specific (min X Bov,Gt,Hrs,Hu,Rb,Rat,Shp Ig)  
115-165-205 Cy3-AffiniPure Goat Anti-Mouse IgG, Fc<sub>γ</sub> Subclass 1 Specific (min X Hu,Bov,Rb Sr Prot)  
115-165-206 Cy3-AffiniPure Goat Anti-Mouse IgG, Fc<sub>γ</sub> Subclass 2a Specific (min X Hu,Bov,Rb Sr Prot)  
115-165-207 Cy3-AffiniPure Goat Anti-Mouse IgG, Fc<sub>γ</sub> Subclass 2b Specific (min X Hu,Bov,Rb Sr Prot)  
115-165-208 Cy3-AffiniPure Goat Anti-Mouse IgG, Fc<sub>γ</sub> Subclass 2c Specific (min X Hu,Bov,Rb Sr Prot)  
115-165-209 Cy3-AffiniPure Goat Anti-Mouse IgG, Fc<sub>γ</sub> Subclass 3 Specific (min X Hu,Bov,Rb Sr Prot)  
115-166-003 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Goat Anti-Mouse IgG (H+L)  
115-166-006 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Goat Anti-Mouse IgG, F(ab')<sub>2</sub> Fragment Specific  
115-166-008 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Goat Anti-Mouse IgG, Fc<sub>γ</sub> Fragment Specific  
115-166-020 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Goat Anti-Mouse IgM, μ Chain Specific  
115-166-062 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Goat Anti-Mouse IgG (H+L) (min X Hu,Bov,Hrs Sr Prot)  
115-166-068 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Goat Anti-Mouse IgG + IgM (H+L) (min X Hu,Bov,Hrs Sr Prot)  
115-166-071 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Goat Anti-Mouse IgG, Fc<sub>γ</sub> Fragment Specific (min X Hu,Bov,Hrs Sr Prot)  
115-166-072 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Goat Anti-Mouse IgG, F(ab')<sub>2</sub> Fragment Specific (min X Hu,Bov,Hrs Sr Prot)  
115-166-075 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Goat Anti-Mouse IgM, μ Chain Specific (min X Hu,Bov,Hrs Sr Prot)  
115-167-003 Cy3-AffiniPure Fab Fragment Goat Anti-Mouse IgG (H+L)  
115-167-020 Cy3-AffiniPure Fab Fragment Goat Anti-Mouse IgM, μ Chain Specific  
123-165-021 Cy3-AffiniPure Goat Anti-Horseradish Peroxidase  
127-165-099 Cy3-AffiniPure Goat Anti-Armenian Hamster IgG (H+L) (min X Bov Sr Prot)  
127-165-160 Cy3-AffiniPure Goat Anti-Armenian Hamster IgG (H+L) (min X Bov,Hu,Ms,Rb,Rat Sr Prot)  
200-162-037 Cy3-IgG Fraction Monoclonal Mouse Anti-Fluorescein (FITC)  
200-162-156 Cy3-IgG Fraction Monoclonal Mouse Anti-Digoxin  
200-162-211 Cy3-IgG Fraction Monoclonal Mouse Anti-Biotin

205-162-176 Cy3-IgG Fraction Monoclonal Mouse Anti-Goat IgG, Light Chain Specific (min X Hrs,Hu,Ms,Rb,Rat Ig)  
 205-165-108 Cy3-AffiniPure Mouse Anti-Goat IgG (H+L) (min X Ms,Hu,Rb Sr Prot)  
 209-165-082 Cy3-AffiniPure Mouse Anti-Human IgG (H+L) (min X Ms Sr Prot)  
 209-165-088 Cy3-AffiniPure Mouse Anti-Human IgG (H+L) (min X Bov,Hrs,Ms Sr Prot)  
 209-165-097 Cy3-AffiniPure Mouse Anti-Human IgG, F(ab')<sub>2</sub> Fragment Specific (min X Bov,Hrs,Ms Sr Prot)  
 209-165-098 Cy3-AffiniPure Mouse Anti-Human IgG, Fcγ Fragment Specific (min X Bov,Hrs,Ms Sr Prot)  
 211-162-171 Cy3-IgG Fraction Monoclonal Mouse Anti-Rabbit IgG, Light Chain Specific (min X Bov,Gt,Arm Hms,Hrs,Hu,Ms,Rat,Shp Ig)  
 211-165-109 Cy3-AffiniPure Mouse Anti-Rabbit IgG (H+L) (min X Hu,Gt,Ms,Shp Sr Prot)  
 212-165-082 Cy3-AffiniPure Mouse Anti-Rat IgG (H+L) (min X Ms Sr Prot)  
 212-165-104 Cy3-AffiniPure Mouse Anti-Rat IgG, Fcγ Fragment Specific (min X Hu,Bov,Hrs,Ms Sr Prot)  
 212-165-106 Cy3-AffiniPure Mouse Anti-Rat IgG, F(ab')<sub>2</sub> Fragment Specific (min X Hu,Bov,Hrs,Ms Sr Prot)  
 212-165-168 Cy3-AffiniPure Mouse Anti-Rat IgG (H+L) (min X Hu,Bov,Hrs,Ms,Gt,Rb Sr Prot)  
 212-166-168 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Mouse Anti-Rat IgG (H+L) (min X Hu,Bov,Hrs,Ms,Gt,Rb Sr Prot)  
 213-162-177 Cy3-IgG Fraction Monoclonal Mouse Anti-Sheep IgG, Light Chain Specific (min X Bov,Hrs,Hu,Ms,Rb,Rat Ig)  
 301-165-003 Cy3-AffiniPure Rabbit Anti-Bovine IgG (H+L)  
 303-165-003 Cy3-AffiniPure Rabbit Anti-Chicken IgY (IgG) (H+L)  
 303-165-006 Cy3-AffiniPure Rabbit Anti-Chicken IgY (IgG), F(ab')<sub>2</sub> Fragment Specific  
 303-165-008 Cy3-AffiniPure Rabbit Anti-Chicken IgY (IgG), Fc Fragment Specific  
 303-166-003 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Rabbit Anti-Chicken IgY (IgG) (H+L)  
 304-165-003 Cy3-AffiniPure Rabbit Anti-Dog IgG (H+L)  
 304-165-008 Cy3-AffiniPure Rabbit Anti-Dog IgG, Fc Fragment Specific  
 305-165-003 Cy3-AffiniPure Rabbit Anti-Goat IgG (H+L)  
 305-165-006 Cy3-AffiniPure Rabbit Anti-Goat IgG, F(ab')<sub>2</sub> Fragment Specific  
 305-165-008 Cy3-AffiniPure Rabbit Anti-Goat IgG, Fc Fragment Specific  
 305-165-045 Cy3-AffiniPure Rabbit Anti-Goat IgG (H+L) (min X Hu Sr Prot)  
 305-165-046 Cy3-AffiniPure Rabbit Anti-Goat IgG, Fc Fragment Specific (min X Hu Sr Prot)  
 305-165-047 Cy3-AffiniPure Rabbit Anti-Goat IgG, F(ab')<sub>2</sub> Fragment Specific (min X Hu Sr Prot)  
 305-166-003 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Rabbit Anti-Goat IgG (H+L)  
 305-166-006 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Rabbit Anti-Goat IgG, F(ab')<sub>2</sub> Fragment Specific  
 305-166-008 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Rabbit Anti-Goat IgG, Fc Fragment Specific  
 305-166-045 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Rabbit Anti-Goat IgG (H+L) (min X Hu Sr Prot)  
 305-166-046 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Rabbit Anti-Goat IgG, Fc Fragment Specific (min X Hu Sr Prot)  
 305-166-047 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Rabbit Anti-Goat IgG, F(ab')<sub>2</sub> Fragment Specific (min X Hu Sr Prot)  
 305-167-003 Cy3-AffiniPure Fab Fragment Rabbit Anti-Goat IgG (H+L)  
 307-165-003 Cy3-AffiniPure Rabbit Anti-Syrian Hamster IgG (H+L)  
 307-166-003 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Rabbit Anti-Syrian Hamster IgG (H+L)  
 308-165-003 Cy3-AffiniPure Rabbit Anti-Horse IgG (H+L)  
 309-165-003 Cy3-AffiniPure Rabbit Anti-Human IgG (H+L)  
 309-165-006 Cy3-AffiniPure Rabbit Anti-Human IgG, F(ab')<sub>2</sub> Fragment Specific  
 309-165-008 Cy3-AffiniPure Rabbit Anti-Human IgG, Fcγ Fragment Specific  
 309-165-011 Cy3-AffiniPure Rabbit Anti-Human Serum IgA, α Chain Specific  
 309-165-015 Cy3-AffiniPure Rabbit Anti-Human Lactoferrin  
 309-165-064 Cy3-AffiniPure Rabbit Anti-Human IgA+IgG+IgM (H+L)  
 309-165-082 Cy3-AffiniPure Rabbit Anti-Human IgG (H+L) (min X Ms Sr Prot)  
 309-165-095 Cy3-AffiniPure Rabbit Anti-Human IgM, Fc5μ Fragment Specific (min X Ms Sr Prot)  
 309-165-107 Cy3-AffiniPure Rabbit Anti-Human IgG + IgM (H+L) (min X Ms Sr Prot)  
 309-166-003 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Rabbit Anti-Human IgG (H+L)  
 309-166-008 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Rabbit Anti-Human IgG, Fcγ Fragment Specific  
 309-166-043 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Rabbit Anti-Human IgM, Fc5μ Fragment Specific  
 312-165-003 Cy3-AffiniPure Rabbit Anti-Rat IgG (H+L)  
 312-165-020 Cy3-AffiniPure Rabbit Anti-Rat IgM, μ Chain Specific  
 312-165-044 Cy3-AffiniPure Rabbit Anti-Rat IgG + IgM (H+L)  
 312-165-045 Cy3-AffiniPure Rabbit Anti-Rat IgG (H+L) (min X Hu Sr Prot)  
 312-165-046 Cy3-AffiniPure Rabbit Anti-Rat IgG, Fcγ Fragment Specific (min X Hu Sr Prot)  
 312-165-047 Cy3-AffiniPure Rabbit Anti-Rat IgG, F(ab')<sub>2</sub> Fragment Specific (min X Hu Sr Prot)  
 312-165-048 Cy3-AffiniPure Rabbit Anti-Rat IgG + IgM (H+L) (min X Hu Sr Prot)  
 312-165-049 Cy3-AffiniPure Rabbit Anti-Rat IgM, μ Chain Specific (min X Hu Sr Prot)  
 312-166-045 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Rabbit Anti-Rat IgG (H+L) (min X Hu Sr Prot)  
 313-165-003 Cy3-AffiniPure Rabbit Anti-Sheep IgG (H+L)  
 313-165-045 Cy3-AffiniPure Rabbit Anti-Sheep IgG (H+L) (min X Hu Sr Prot)  
 313-165-046 Cy3-AffiniPure Rabbit Anti-Sheep IgG, Fc Fragment Specific (min X Hu Sr Prot)  
 313-165-047 Cy3-AffiniPure Rabbit Anti-Sheep IgG, F(ab')<sub>2</sub> Fragment Specific (min X Hu Sr Prot)  
 313-166-003 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Rabbit Anti-Sheep IgG (H+L)  
 313-167-003 Cy3-AffiniPure Fab Fragment Rabbit Anti-Sheep IgG (H+L)  
 315-165-003 Cy3-AffiniPure Rabbit Anti-Mouse IgG (H+L)  
 315-165-006 Cy3-AffiniPure Rabbit Anti-Mouse IgG, F(ab')<sub>2</sub> Fragment Specific  
 315-165-008 Cy3-AffiniPure Rabbit Anti-Mouse IgG, Fcγ Fragment Specific  
 315-165-020 Cy3-AffiniPure Rabbit Anti-Mouse IgM, μ Chain Specific  
 315-165-044 Cy3-AffiniPure Rabbit Anti-Mouse IgG + IgM (H+L)  
 315-165-045 Cy3-AffiniPure Rabbit Anti-Mouse IgG (H+L) (min X Hu Sr Prot)  
 315-165-046 Cy3-AffiniPure Rabbit Anti-Mouse IgG, Fcγ Fragment Specific (min X Hu Sr Prot)  
 315-165-047 Cy3-AffiniPure Rabbit Anti-Mouse IgG, F(ab')<sub>2</sub> Fragment Specific (min X Hu Sr Prot)  
 315-165-048 Cy3-AffiniPure Rabbit Anti-Mouse IgG + IgM (H+L) (min X Hu Sr Prot)  
 315-165-049 Cy3-AffiniPure Rabbit Anti-Mouse IgM, μ Chain Specific (min X Hu Sr Prot)  
 315-166-003 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Rabbit Anti-Mouse IgG (H+L)  
 315-166-045 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Rabbit Anti-Mouse IgG (H+L) (min X Hu Sr Prot)  
 315-166-046 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Rabbit Anti-Mouse IgG, Fcγ Fragment Specific (min X Hu Sr Prot)  
 315-166-047 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Rabbit Anti-Mouse IgG, F(ab')<sub>2</sub> Fragment Specific (min X Hu Sr Prot)  
 315-167-003 Cy3-AffiniPure Fab Fragment Rabbit Anti-Mouse IgG (H+L)  
 323-165-021 Cy3-AffiniPure Rabbit Anti-Horseradish Peroxidase  
 415-165-166 Cy3-AffiniPure Rat Anti-Mouse IgG (H+L) (min X Hu,Bov,Hrs,Rat,Rb Sr Prot)  
 515-165-003 Cy3-AffiniPure Sheep Anti-Mouse IgG (H+L)  
 515-165-062 Cy3-AffiniPure Sheep Anti-Mouse IgG (H+L) (min X Hu,Bov,Hrs Sr Prot)  
 515-165-071 Cy3-AffiniPure Sheep Anti-Mouse IgG, Fcγ Fragment Specific (min X Hu,Bov,Hrs Sr Prot)  
 515-165-072 Cy3-AffiniPure Sheep Anti-Mouse IgG, F(ab')<sub>2</sub> Fragment Specific (min X Hu,Bov,Hrs Sr Prot)  
 703-165-155 Cy3-AffiniPure Donkey Anti-Chicken IgY (IgG) (H+L) (min X Bov,Gt,GP,Sy Hms,Hrs,Hu,Ms,Rb,Rat,Shp Sr Prot)  
 703-166-155 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Donkey Anti-Chicken IgY (IgG) (H+L) (min X Bov,Gt,GP,Sy Hms,Hrs,Hu,Ms,Rb,Rat,Shp Sr Prot)  
 705-165-003 Cy3-AffiniPure Donkey Anti-Goat IgG (H+L)  
 705-165-147 Cy3-AffiniPure Donkey Anti-Goat IgG (H+L) (min X Ck,GP,Sy Hms,Hrs,Hu,Ms,Rb,Rat Sr Prot)  
 705-166-147 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Donkey Anti-Goat IgG (H+L) (min X Ck,GP,Sy Hms,Hrs,Hu,Ms,Rb,Rat Sr Prot)  
 706-165-148 Cy3-AffiniPure Donkey Anti-Guinea Pig IgG (H+L) (min X Bov,Ck,Gt,Sy Hms,Hrs,Hu,Ms,Rb,Rat,Shp Sr Prot)  
 706-166-148 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Donkey Anti-Guinea Pig IgG (H+L) (min X Bov,Ck,Gt,Sy Hms,Hrs,Hu,Ms,Rb,Rat,Shp Sr Prot)  
 709-165-073 Cy3-AffiniPure Donkey Anti-Human IgM, Fc5μ Fragment Specific (min X Bov,Hrs Sr Prot)  
 709-165-098 Cy3-AffiniPure Donkey Anti-Human IgG, Fcγ Fragment Specific (min X Bov,Hrs,Ms Sr Prot)  
 709-165-149 Cy3-AffiniPure Donkey Anti-Human IgG (H+L) (min X Bov,Ck,Gt,GP,Sy Hms,Hrs,Ms,Rb,Rat,Shp Sr Prot)  
 709-166-073 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Donkey Anti-Human IgM, Fc5μ Fragment Specific (min X Bov,Hrs Sr Prot)  
 709-166-098 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Donkey Anti-Human IgG, Fcγ Fragment Specific (min X Bov,Hrs,Ms Sr Prot)  
 709-166-149 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Donkey Anti-Human IgG (H+L) (min X Bov,Ck,Gt,GP,Sy Hms,Hrs,Ms,Rb,Rat,Shp Sr Prot)  
 711-165-152 Cy3-AffiniPure Donkey Anti-Rabbit IgG (H+L) (min X Bov,Ck,Gt,GP,Sy Hms,Hrs,Hu,Ms,Rat,Shp Sr Prot)  
 711-166-152 Cy3-AffiniPure F(ab')<sub>2</sub> Fragment Donkey Anti-Rabbit IgG (H+L) (min X Bov,Ck,Gt,GP,Sy Hms,Hrs,Hu,Ms,Rat,Shp Sr Prot)  
 711-167-003 Cy3-AffiniPure Fab Fragment Donkey Anti-Rabbit IgG (H+L)  
 712-165-150 Cy3-AffiniPure Donkey Anti-Rat IgG (H+L) (min X Bov,Ck,Gt,GP,Sy Hms,Hrs,Hu,Rb,Shp Sr Prot)

712-165-153	Cy3-AffiniPure Donkey Anti-Rat IgG (H+L) (min X Bov,Ck,Gt,GP,Sy Hms,Hrs,Hu,Ms,Rb,Shp Sr Prot)
712-166-150	Cy3-AffiniPure F(ab') <sub>2</sub> Fragment Donkey Anti-Rat IgG (H+L) (min X Bov,Ck,Gt,GP,Sy Hms,Hrs,Hu,Rb,Shp Sr Prot)
712-166-153	Cy3-AffiniPure F(ab') <sub>2</sub> Fragment Donkey Anti-Rat IgG (H+L) (min X Bov,Ck,Gt,GP,Sy Hms,Hrs,Hu,Ms,Rb,Shp Sr Prot)
712-167-003	Cy3-AffiniPure Fab Fragment Donkey Anti-Rat IgG (H+L)
713-165-003	Cy3-AffiniPure Donkey Anti-Sheep IgG (H+L)
713-165-147	Cy3-AffiniPure Donkey Anti-Sheep IgG (H+L) (min X Ck,GP,Sy Hms,Hrs,Hu,Ms,Rb,Rat Sr Prot)
713-166-147	Cy3-AffiniPure F(ab') <sub>2</sub> Fragment Donkey Anti-Sheep IgG (H+L) (min X Ck,GP,Sy Hms,Hrs,Hu,Ms,Rb,Rat Sr Prot)
715-165-020	Cy3-AffiniPure Donkey Anti-Mouse IgM, $\mu$ Chain Specific
715-165-140	Cy3-AffiniPure Donkey Anti-Mouse IgM, $\mu$ Chain Specific (min X Hu,Bov,Hrs,Rat Sr Prot)
715-165-150	Cy3-AffiniPure Donkey Anti-Mouse IgG (H+L) (min X Bov,Ck,Gt,GP,Sy Hms,Hrs,Hu,Rb,Shp Sr Prot)
715-165-151	Cy3-AffiniPure Donkey Anti-Mouse IgG (H+L) (min X Bov,Ck,Gt,GP,Sy Hms,Hrs,Hu,Rb,Rat,Shp Sr Prot)
715-166-020	Cy3-AffiniPure F(ab') <sub>2</sub> Fragment Donkey Anti-Mouse IgM, $\mu$ Chain Specific
715-166-150	Cy3-AffiniPure F(ab') <sub>2</sub> Fragment Donkey Anti-Mouse IgG (H+L) (min X Bov,Ck,Gt,GP,Sy Hms,Hrs,Hu,Rb,Shp Sr Prot)
715-166-151	Cy3-AffiniPure F(ab') <sub>2</sub> Fragment Donkey Anti-Mouse IgG (H+L) (min X Bov,Ck,Gt,GP,Sy Hms,Hrs,Hu,Rb,Rat,Shp Sr Prot)
715-167-003	Cy3-AffiniPure Fab Fragment Donkey Anti-Mouse IgG (H+L)
805-165-180	Cy3-AffiniPure Bovine Anti-Goat IgG (H+L) (min X Bov ,Ck,GP,Sy Hms,Hrs,Hu,Ms,Rb,Rat Sr Prot)

**Product type:** Freeze-dried powder

**Other means of identification:** None

## 1.2 Revelant identified uses of the substance or mixture identifier

For *in vitro* research use only. Not for diagnostic or therapeutic use. This is not a medical device. Contact suppliers for specific applications.

## 1.3 Details of the supplier of the safety data sheet

### European Contact

Jackson ImmunoResearch Europe LTD  
Unit 7, Acorn Business Centre  
Oaks Drive, Newmarket,  
Suffolk, CB8 7SY, UK  
T: +44 (0) 1638 782616  
F: +44 (0) 1638 668462  
cuserv@jireurope.com  
www.jireurope.com

### Manufacturer

Jackson ImmunoResearch Laboratories, Inc.  
872 West Baltimore Pike  
West Grove, PA 19390  
T: 800-367-5296, 610-869-4024  
F: 610-869-0171  
cuserv@jacksonimmuno.com  
tech@jacksonimmuno.com  
www.jacksonimmuno.com

**E-mail address of the person responsible for this SDS:** tech@jacksonimmuno.com

## 1.4 Emergency telephone number

### Emergency Contact

**Telephone number:** CHEMTREC:  
800-424-9300  
OUTSIDE USA:  
703-527-3887

## SECTION 2: Hazards identification

### 2.1 Classification of the substance or mixture

**Product definition:** Mixture

#### Classification according to Directive 1999/45/E [DPD]

##### Europe

This product is not classified as dangerous after rehydration according to directive 1999/45/EC and its amendments.

**Classification:** Not classified.

See Section 16 for the full text of the R phrases or H statements declared above.

See Section 11 for more detailed information on health effects and symptoms.

### 2.2 Label elements

**Hazard symbol or symbols:** N/A

**Indication of danger:** N/A

**Risk phrases:** After rehydration, this product is not classified according to EU legislation.

**Safety phrases:** Not applicable.

**Hazardous ingredients:** The only danger of this product is associated with sodium azide which is present in a very small amount. After rehydration, sodium azide is below the threshold level of 1% for a toxic chemical.

**Supplemental label elements:** Not applicable.

#### Special packaging requirements

**Containers to be fitted with child-resistant fastenings:** Not applicable.

**Tactile warning of danger:** Not applicable.

### 2.3 Other hazards

**Other hazards which do not result in classification:** Products of human origin may contain agents which pose a potential biological hazard to humans. The source materials (donor blood) for all products of human origin were tested according to FDA guidelines for the detection of Hepatitis B surface antigen, antibodies to HIV, antibodies to Hepatitis C, HIV-1 antigens, and Syphilis. Each donor blood unit was negative for each test. However, no test method can provide total assurance that these infectious agents are absent.

## SECTION 3: Composition/information on ingredients

**Substance/mixture:** Mixture

Chemical Name	CAS#	EC #	% (w/w)
Sodium Azide	26628-22-8	247-852-1	2 [0.05% (w/v) after rehydration]
Sodium Phosphate	7558-79-4	231-448-7	4
Cy3-conjugated antibody, serum protein, or streptavidin	N/A	N/A	5
Sodium Chloride	7647-14-5	231-598-3	44
Bovine Serum Albumin	N/A	N/A	45

The mixture is not considered to be hazardous after rehydration for use.

## SECTION 4: First aid measures

### 4.1 Description of first aid measures

**Eye contact:** If this product enters the eyes, flush the eyes with gently running water for at least 15 minutes. If inflammation occurs, get medical attention.

**Inhalation:** Vapors of these products are likely to be only water vapors, so no adverse health effects are expected if vapors are inhaled. If irritation occurs, get medical attention.

**Skin contact:** Basic hygiene should prevent any problems. If contact with these products leads to reddening, inflammation, or irritation, flush exposed area with running water and get medical attention.

**Ingestion:** Wash out mouth with water. Remove victim to fresh air and keep at rest in a position comfortable for breathing. Give small quantities of water to drink. Do not induce vomiting unless directed by medical personnel. These products are for *in vitro* research use only, not for household, diagnostic, or therapeutic use. They are not medical devices. If these products are accidentally swallowed, no adverse health effects are expected. However, no special precautions are taken to remove or detect the possible presence of endotoxin or pyrogens. If fever or adverse effects are experienced, get medical attention.

**Protection of first-aiders:** No action shall be taken involving any personal risk or without suitable training.

### 4.2 Most important symptoms and effects, both acute and delayed

#### Potential acute health effects

**Eye contact:** No known significant effects or critical hazards.

**Inhalation:** No known significant effects or critical hazards.

**Skin contact:** No known significant effects or critical hazards.

**Ingestion:** No known significant effects or critical hazards.

#### Over-exposure signs/symptoms

**Eye contact:** No specific data.

**Inhalation:** No specific data.

**Skin Contact:** No specific data.

**Ingestion:** No specific data.

### 4.3 Indication of any immediate medical attention and special treatment needed

**Notes to physician:** Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.

**Specific treatments:** No specific treatment.

## SECTION 5: Fire-fighting measures

5.1

### Extinguishing media

**Suitable extinguishing media:** Use an extinguishing agent suitable for the surrounding fire.

**Unsuitable extinguishing media:** None known.

### 5.2 Special hazards arising from the substance or mixture

**Hazards from the substance or mixture:** In a fire or if heated, a pressure increase will occur and the container may burst.

**Hazardous combustion products:** Decomposition products may include oxides of carbon, nitrogen, and phosphorus in very small quantities.

### 5.3 Advice for fire fighters

**Special precautions for fire fighters:** Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.

**Special protective equipment for fire fighters:** Fire fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire fighters (including helmets, protective boots, and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.

## SECTION 6. Accidental release measures

6.1 Personal

### precautions, protective equipment, and emergency procedures

**For non-emergency personnel:** No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas.

Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Put on appropriate personal protective equipment.

**For emergency responders:**

**6.2 Environmental precautions:** Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains, and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil, or air).

### 6.3 Methods and materials for containment and cleaning up

**Small spill:** Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water soluble. Alternatively, or if water insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

**Large spill:** Stop leak if without risk. Move containers from spill area. Prevent entry into sewers, water courses, basements, or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with non-combustible, absorbent material, e.g. sand, earth, vermiculite, or diatomaceous earth and place in container for disposal according to local regulations. Dispose of via licensed waste disposal contractor.

**6.4 Reference to other sections:** See Section 1 for emergency contact information.

See Section 8 for information on appropriate personal protective equipment.  
See Section 13 for additional waste treatment information.

## SECTION 7: Handling and storage

The information in this section contains generic advice and guidelines. The list of Identified Uses in Section 1 should be consulted for any available use specific information provided in the Exposure Scenario(s).

### 7.1 Precautions for safe handling

**Protective measures:** Put on appropriate protective equipment (see Section 8).

**Advice on general occupational hygiene:** Eating, drinking, and smoking should be prohibited in areas where material is handled, stored, and processed. Workers should wash hands and face before eating, drinking, and smoking. Remove contaminated clothing and protective equipment entering eating areas. See also Section 8 for additional information on hygiene measures.

**7.2 Conditions for safe storage, including any incompatibilities:** Store at 2-8 ° C under sterile conditions. Store in original container away from incompatible materials (see Section 10) and food and drink. Keep container tightly sealed until ready to use. Prepare working dilution fresh each day. Remove aliquots for dilution and reseal container under sterile conditions. Do not store in unlabeled container. Use appropriate containment to avoid environmental contamination. Consult Product Specification sheets for additional storage information.

### 7.3 Specific end uses

**Recommendations:** Not available.

**Industrial sector specific solutions:** Not available.

## SECTION 8: Exposure controls/personal protection

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

### 8.1 Control parameters

#### Occupational exposure limits

**Europe:** No exposure limit value known.

**Recommended monitoring procedures:** If this product contains ingredients with exposure limits, personal, workplace atmosphere, or biological monitoring may be required to determine the effectiveness of the ventilation or other control measures and/or the necessity to use respiratory protective equipment. Reference should be made to European Standard EN689 for methods for the assessment of exposure by inhalation to chemical agents and national guidance documents for methods for the determination of hazardous substances.

#### Derived effect levels

No DELs available

#### Predicted effect concentrations

No PECs available

### 8.2 Exposure controls

**Appropriate engineering controls:** No special ventilation requirements. Good general ventilation should be sufficient to control worker exposure to airborne contaminants. If this product contains ingredients with exposure limits, use process enclosures, local exhaust ventilation, or other engineering controls to keep worker exposure below any recommended or statutory limits.

#### Individual protection measures

**Hygiene measures:** Wash hands, forearms, and face thoroughly after handling chemical products, before eating, smoking, and using the laboratory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure the eyewash station and safety showers are close to the workstation location.

**Eye/face protection:** Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, or dusts.

#### Skin protection

**Hand protection:** Chemical resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary.

**Body protection:** Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

**Other skin protection:** Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

**Respiratory protection:** Use a properly-fitted, air-purifying, or air-fed respirator complying with an approved standard if a risk assessment indicates this is a necessity. Respirator selection must be on known or anticipated exposure levels, the hazards of the product and the safe working limits of the selected respirator.

**Environmental exposure controls:** Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters, or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

## SECTION 9: Physical and chemical properties

### 9.1 Information

#### on basic physical and chemical properties

##### Appearance

**Physical state:** Liquid

**Color:** Colorless, as water

**Odor:** Odorless, as water

**Odor threshold:** Not available

**pH:** 7.6

**Melting point/freezing point:** Not available

**Initial boiling point and boiling range:** Not available

**Flash point:** Not available

**Evaporation rate:** Not available

**Flammability:** Not available

**Burning time:** Not available

**Burning rate:** Not available

**Upper/lower flammability or explosive limits:** Not available

**Vapor pressure:** Not available

**Vapor density:** Not available

**Relative density:** Not available

**Solubility(ies):** Soluble in warm and cold water  
**Partition coefficient:** n-octanol/water  
**Auto-ignition temperature:** Not available  
**Decomposition temperature:** Not available  
**Viscosity:** Not available  
**Explosive properties:** Not available  
**Oxidizing properties:** Not available

## 9.2 Other information

No additional information

## SECTION 10: Stability and reactivity

No specific test data related to reactivity available for this product or its ingredients.

### 10.1 Reactivity:

**10.2 Chemical stability:** The product is stable.

**10.3 Possibility of hazardous reactions:** Under normal conditions of storage and use, hazardous reactions will not occur.

**10.4 Conditions to avoid:** No specific data.

**10.5 Incompatible materials:** No specific data.

**10.6 Hazardous decomposition products:** Under normal conditions of storage and use, hazardous decomposition products will not be produced.

## SECTION 11: Toxicological information

### 11.1 Information on toxicological effects

#### Acute toxicity

**Sodium Chloride:** Oral Rat, LD50, 3,000 mg/kg

**Sodium Phosphate:** Oral Rat, LD50, 17g/kg

**Sodium Azide:** Oral Rat, LD50, 27 mg/kg

**Antibody/Serum Protein:** Not established

#### Irritation/Corrosion

**Conclusion/Summary:** Not available.

#### Sensitizer

**Conclusion/Summary:** Not available.

#### Mutagenicity

**Conclusion/Summary:** Not available

#### Carcinogenicity

**Conclusion/Summary:** Not available

#### Reproductive toxicity

**Conclusion/Summary:** Not available

#### Teratogenicity

**Conclusion/Summary:** Not available

**Information on the likely routes of exposure:** Routes of entry anticipated: Oral, Dermal, and Inhalation

#### Potential acute health effects

**Inhalation:** No known significant effects or critical hazards.

**Ingestion:** No known significant effects or critical hazards.

**Skin contact:** No known significant effects or critical hazards.

**Eye contact:** No known significant effects or critical hazards.

#### Symptoms related to the physical, chemical, and toxicological characteristics

**Inhalation:** No specific data

**Ingestion:** No specific data

**Skin contact:** No specific data

**Eye contact:** No specific data

#### Delayed, immediate, and chronic effects from short and long term exposure

##### Short term exposure

**Potential immediate effects:** Not available

**Potential delayed effects:** Not available

##### Long term effects

**Potential immediate effects:** Not available

**Potential delayed effects:** Not available

#### Potential chronic health effects

**Conclusion/Summary:** Not available

General: No known significant effects or critical hazards.

Carcinogenicity: No known significant effects or critical hazards.

Mutagenicity: No known significant effects or critical hazards.

Teratogenicity: No known significant effects or critical hazards.

Developmental effects: No known significant effects or critical hazards.

Fertility effects: No known significant effects or critical hazards.

**Other information:** Not available

## SECTION 12: Ecological information

### 12.1 Toxicity

**Conclusion/Summary:** Not available

### 12.2 Persistence and degradability

**Conclusion/Summary:** Not available

**12.3 Bioaccumulative potential.** Not available

### 12.4 Mobility in soil

**Soil/water partition coefficient:** Not available

**Mobility:** Not available

### 12.5 Results of PBT and vPvB assessment

**PBT:** Not applicable

**vPvB:** Not applicable

**12.6 Other adverse effects:** No known significant effects or critical hazards.

## SECTION 13. Disposal considerations

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

### 13.1 Waste treatment methods

#### Product

**Methods of disposal:** The generation of waste should be avoided or minimized wherever possible. Significant quantities of waste product residues should not be disposed of via the foul sewer but processed in a suitable effluent treatment plant. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Disposal of this product, solutions, and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible. This material and its container must be disposed of in a safe way. Empty containers or liners may retain some product residues. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains, and sewers.

**Hazardous waste:** Within the present knowledge of the supplier, this product is not regarded as hazardous waste, as defined by EU Directive 91/689/EEC.

#### Packaging

**Methods of disposal:** The generation of waste should be avoided or minimized whenever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.

**Special precautions:** This material and its container must be disposed of in a safe way. Empty containers or liners may retain some product residues. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains, and sewers.

## SECTION 14: Transport information

	ADR/RID	ADN/ADNR	IMDG	IATA
14.1 UN number	Not available	Not available	Not available	Not available
14.2 UN proper shipping name	Not available	Not available	-	-
14.3 Transport hazard class(es)	Not available	Not available	-	-
14.4 Packing group	-	-	-	-
14.5 Environmental hazards	No	No	No	No
14.6 Special precaution for user	Not available	Not available	Not available	Not available
Additional information	-	-	-	-

**14.7 Transport in bulk according to Annex II of MARPOL 73/78 and the and the IBC Code:** Not available.

## SECTION 15: Regulatory information

### 15.1 Safety, health, and environmental regulations/legislation specific for the substance or mixture

#### EU Regulation (EC) No. 1907/2006 (REACH)

##### Annex XIV - List of substances subject to authorization

###### Substances of very high concern

None of the components are listed.

**Annex XVII - Restrictions on the manufacture, placing on the market, and use of certain dangerous substances, mixtures, and articles:** Not applicable.

#### Other EU regulations

**Europe inventory:** Not determined.

**Black List Chemicals:** Not listed.

**Priority List Chemicals:** Not listed.

**Integrated pollution prevention and control list (IPPC) - Air:** Not listed.

**IPPC - Water:** Not listed.

#### National Regulations

**15.2 Chemical Safety Assessment:** This product contains substances for which Chemical Safety Assessments are still required.

## SECTION 16: Other information

**Abbreviations and acronyms:** ATE = Acute Toxicity Estimate

CLP = Classification, Labelling, and Packaging Regulation [Regulation (EC) No. 1272/2008]

DNEL = Derived No Effect Level

EUH statement = CLP-specific Hazard Statement

PNEC = Predicted No Effect Concentration

RRN = REACH Registration Number

#### Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Not classified

#### Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Classification	Justification
----------------	---------------



## Europe

**Full text of abbreviation H statements:** Not applicable.

**Full text of classifications [CLP/GHS]:** Not applicable.

**Full text of abbreviated R phrases:** Not applicable.

**Full text of classifications[DSD/DPD]:** Not applicable.

**Date of printing:** 10/10/2010

**Date of issue/Date of revision:** 5/9/2012

**Date of previous issue:** No previous validation.

**Version:** 1.01

## Notice to reader

**To the best of our knowledge, the information contained herein is accurate. However, neither the above named supplier, nor any of its subsidiaries, assumes any liability whatsoever for the accuracy or completeness of the information contained herein.**

**Final determination of suitability of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist.**

\*Cy is a trademark of GE Healthcare Bio-Sciences Ltd. Jackson ImmunoResearch is licensed to manufacture and sell conjugates of Cy2, Cy3, and Cy5 reactive dyes under US Patent Number 5,268,486 and other patents pending.